PharVision Advisers’s Cencora COR Stock Holding History

PharVision Advisers’s Portfolio COR Stock Details COR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,016	Closed	-$453K	–	314
2024 Q4	$453K	Buy	+2,016	New	+$474K	0.38%	58

Other funds holding COR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WBA

Walgreens Boots Alliance Deerfield, Illinois $2.24B AUM 36.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's COR Position: Q1 2025 in Review

PharVision Advisers sold out of Cencora (COR) in Q1 2025, closing a stake of 2,016 shares — an estimated $453K sold.

PharVision Advisers first reported a position in COR in Q4 2024 and held it in 1 quarter. The position peaked at $453K in Q4 2024. 1,291 funds tracked by Wall St. Rank hold COR as of Q1 2025.

PharVision Advisers reported no remaining Cencora position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 2,016 Cencora shares in Q1 2025, an estimated $453K.
PharVision Advisers first reported a position in Cencora in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Cencora position peaked at $453K in Q4 2024.
1,291 funds tracked by Wall St. Rank held Cencora as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.